Clinical trial · Interventional
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to determine the response rate of patients with recurrent platinum resistant ovarian cancer when treated with oral minoxidil. Secondary objectives include estimating the time to disease progression while on minoxidil and to describe the toxicities of minoxidil when used for patients with recurrent platinum resistant ovarian cancer. An exploratory objective is to evaluate if efficacy of minoxidil is improved in patients that have the Kir6/SUR complex versus those that do not.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Minoxidil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Participants in this arm will be treated with minoxidil. This treatment will be given daily by mouth.
- interventionNames
- Drug: Minoxidil
Primary outcomes (1)
- measure
- Overall response rate (ORR)
- timeFrame
- At the end of Cycle 2 (each cycle is 28 days)
- description
- The ORR is defined as the percentage of participants who experience a complete response (CR), partial response (PR), or stable disease (SD) as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0)
Secondary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria * Participants must have recurrent platinum resistant ovarian cancer. Histologic documentation of the recurrence is not required. * Participants must have platinum resistant disease defined as recurrence less than 6 months after initial platinum based treatment. * Participants must be greater than or equal to 18 years of age. * Participants must have an Eastern Cooperative Group (ECOG) Performance Status (PS) less than or equal to 2. * Participants must be able to take oral medications. Exclusion Criteria * Participants must not have had chemotherapy or radiotherapy within 4 weeks * Participants must not be receiving any other investigational agents. * Participants must not have brain metastases * Participants must not have allergic reactions to minoxidil * Participants must not have congestive heart failure * Participants must not have history of cardiac disease * Participants must not have uncontrolled hypertension * Participants must not be on dialysis
References
Publications (0)
Data not yet available